Brief: Merck’S Winrevair met primary endpoint in phase 2 CADENCE study in adults with combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

Cadence Design Systems

18/11/2025 11:54

Nov 18 (Reuters) - Merck & Co Inc MRK.N

MERCK’S WINREVAIR™ (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN PHASE 2 CADENCE STUDY IN ADULTS WITH COMBINED POST- AND PRECAPILLARY PULMONARY HYPERTENSION (CPCPH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

MERCK & CO INC - WINREVAIR SHOWS SIGNIFICANT REDUCTION IN PULMONARY VASCULAR RESISTANCE

MERCK & CO INC - WINREVAIR MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY

Source text: nBw54T8BDa

Further company coverage: MRK.N

 ((Reuters.Briefs@thomsonreuters.com;))